Erratum: TGFβ Activated Kinase 1 (TAK1) at the Crossroad of B Cell Receptor and Toll-Like Receptor 9 Signaling Pathways in Human B Cells (PLoS ONE (2014) 9:5 (e96381) DOI: 10.1371/journal.pone.0096381);TGFβ activated kinase 1 (TAK1) at the crossroad of B cell receptor and toll-like receptor 9 signaling pathways in human B cells

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Szili, Dániel ^a   Bankó, Zsuzsanna ^a   Tóth, Eszter Angéla ^a   Nagy, György ^b,c   Rojkovich, Bernadette ^b   Gáti, Tamás ^b   Simon, Melinda ^a,c   Hérincs, Zoltán ^a,d   Sármay, Gabriella ^a  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b Buda Hospital of Hospitaller Brothers of St John ^*  (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d Diagnosticum Ltd   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; B LYMPHOCYTE RECEPTOR; CD19 ANTIGEN; CD27 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA; CPG-OLIGONUCLEOTIDE; IMMUNOGLOBULIN G; LYMPHOCYTE ANTIGEN RECEPTOR; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, HUMAN;

ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; CELL PROLIFERATION; GENETICS; LYMPHOCYTE ACTIVATION; METABOLISM;

B-LYMPHOCYTES; CELL PROLIFERATION; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84900458649     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0265030     Document Type: Erratum

References (73)

1. Niiro H, Clark EA (2002) Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2: 945-956. (Pubitemid 37323215)
2. Grimaldi CM, Hicks R, Diamond B (2005) B cell selection and susceptibility to autoimmunity. J Immunol 174: 1775-1781. (Pubitemid 40223915)
3. Peng SL (2005) Signaling in B cells via Toll-like receptors. Curr Opin Immunol 17: 230-236.
4. Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6: 823-835.
5. Patke A, Mecklenbrauker I, Tarakhovsky A (2004) Survival signaling in resting B cells. Curr Opin Immunol 16: 251-255. (Pubitemid 38328726)
6. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, et al. (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189: 1747-1756. (Pubitemid 29272691)
7. Treml JF, Hao Y, Stadanlick JE, Cancro MP (2009) The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 53: 1-16.
8. Nakano S, Morimoto S, Suzuki J, Nozawa K, Amano H, et al. (2008) Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus. Rheumatology (Oxford) 47: 145-149. (Pubitemid 351168222)
9. Capolunghi F, Cascioli S, Giorda E, Rosado MM, Plebani A, et al. (2008) CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol 180: 800-808.
10. Craxton A, Draves KE, Gruppi A, Clark EA (2005) BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 202: 1363-1374. (Pubitemid 41668739)
11. Bossen C, Schneider P (2006) BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 18: 263-275. (Pubitemid 44287558)
12. Khan WN (2009) B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 183: 3561-3567.
13. Fu L, Lin-Lee YC, Pham LV, Tamayo AT, Yoshimura LC, et al. (2009) BAFFR promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood 113: 4627-4636.
14. Schneider P, Tschopp J (2003) BAFF and the regulation of B cell survival. Immunol Lett 88: 57-62. (Pubitemid 36835851)
15. Binard A, Le Pottier L, Saraux A, Devauchelle-Pensec V, Pers JO, et al. (2008) Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus? J Autoimmun 30: 63-67.
16. Swee LK, Tardivel A, Schneider P, Rolink A (2010) Rescue of the mature B cell compartment in BAFF-deficient mice by treatment with recombinant Fc-BAFF. Immunol Lett 131: 40-48.
17. Carter LM, Isenberg DA, Ehrenstein MR (2013) Elevated serum B-cell activating factor (BAFF/BLyS) is associated with rising anti-dsDNA antibody levels and flare following B-cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum.
18. Ramakrishnan P, Wang W, Wallach D (2004) Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB- inducing kinase. Immunity 21: 477-489. (Pubitemid 39370504)
19. Patke A, Mecklenbrauker I, Erdjument-Bromage H, Tempst P, Tarakhovsky A (2006) BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism. J Exp Med 203: 2551-2562. (Pubitemid 44664624)
20. Otipoby KL, Sasaki Y, Schmidt-Supprian M, Patke A, Gareus R, et al. (2008) BAFF activates Akt and Erk through BAFF-R in an IKK1-dependent manner in primary mouse B cells. Proc Natl Acad Sci U S A 105: 12435-12438.
21. Yamada T, Zhang K, Yamada A, Zhu D, Saxon A (2005) B lymphocyte stimulator activates p38 mitogen-activated protein kinase in human Ig class switch recombination. Am J Respir Cell Mol Biol 32: 388-394. (Pubitemid 40629323)
22. Kim HA, Seo GY, Kim PH (2011) Macrophage-derived BAFF induces AID expression through the p38MAPK/CREB and JNK/AP-1 pathways. J Leukoc Biol 89: 393-398.
23. Su TT, Guo B, Kawakami Y, Sommer K, Chae K, et al. (2002) PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol 3: 780-786.
24. Shinohara H, Kurosaki T (2009) Comprehending the complex connection between PKCbeta, TAK1, and IKK in BCR signaling. Immunol Rev 232: 300-318.
25. Adhikari A, Xu M, Chen ZJ (2007) Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26: 3214-3226. (Pubitemid 46763016)
26. Wang C, Deng L, Hong M, Akkaraju GR, Inoue J, et al. (2001) TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412: 346-351. (Pubitemid 32694385)
27. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, et al. (1999) The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398: 252-256.
28. Kawai T, Akira S (2006) TLR signaling. Cell Death Differ 13: 816-825.
29. He B, Santamaria R, Xu W, Cols M, Chen K, et al. (2010) The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol 11: 836-845.
30. Schuman J, Chen Y, Podd A, Yu M, Liu HH, et al. (2009) A critical role of TAK1 in B-cell receptor-mediated nuclear factor kappaB activation. Blood 113: 4566-4574.
31. Chen ZJ (2012) Ubiquitination in signaling to and activation of IKK. Immunol Rev 246: 95-106.
32. Wan YY, Chi H, Xie M, Schneider MD, Flavell RA (2006) The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat Immunol 7: 851-858. (Pubitemid 44084092)
33. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, et al. (2005) Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 6: 1087-1095. (Pubitemid 41541786)
34. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, et al. (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416: 603-607. (Pubitemid 34406754)
35. Yu CC, Mamchak AA, DeFranco AL (2003) Signaling mutations and autoimmunity. Curr Dir Autoimmun 6: 61-88.
36. McGaha TL, Sorrentino B, Ravetch JV (2005) Restoration of tolerance in lupus by targeted inhibitory receptor expression. Science 307: 590-593. (Pubitemid 40165683)
37. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, et al. (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20: 785-798. (Pubitemid 38757447)
38. Rawlings DJ, Schwartz MA, Jackson SW, Meyer-Bahlburg A (2012) Integration of B cell responses through Toll-like receptors and antigen receptors. Nat Rev Immunol 12: 282-294.
39. Hancz A, Koncz G, Szili D, Sarmay G (2012) TLR9-mediated signals rescue B-cells from Fas-induced apoptosis via inactivation of caspases. Immunol Lett 143: 77-84.
40. Biro A, Sarmay G, Rozsnyay Z, Klein E, Gergely J (1992) A trypsin-like serine protease activity on activated human B cells and various B cell lines. Eur J Immunol 22: 2547-2553.
41. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A (1983) A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 65: 109-121. (Pubitemid 14203438)
42. Duddy ME, Alter A, Bar-Or A (2004) Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 172: 3422-3427. (Pubitemid 38337921)
43. Agrawal S, Gupta S (2011) TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol 31: 89-98.
44. Poeck H, Wagner M, Battiany J, Rothenfusser S, Wellisch D, et al. (2004) Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Blood 103: 3058-3064. (Pubitemid 38451681)
45. Taniguchi F, Harada T, Miyakoda H, Iwabe T, Deura I, et al. (2009) TAK1 activation for cytokine synthesis and proliferation of endometriotic cells. Mol Cell Endocrinol 307: 196-204.
46. Arpin C, Banchereau J, Liu YJ (1997) Memory B cells are biased towards terminal differentiation: a strategy that may prevent repertoire freezing. J Exp Med 186: 931-940. (Pubitemid 27407354)
47. Geffroy-Luseau A, Chiron D, Descamps G, Jego G, Amiot M, et al. (2011) TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells. Front Immunol 2: 83.
48. Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, et al. (2002) DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 3: 822-829.
49. Iwata S, Yamaoka K, Niiro H, Nakano K, Wang SP, et al. (2012) Amplification of Toll-like receptor-mediated signaling through spleen tyrosine kinase in human B-cell activation. J Allergy Clin Immunol 129: 1594-1601 e1592.
50. Yi AK, Yoon JG, Krieg AM (2003) Convergence of CpG DNA- and BCRmediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. Int Immunol 15: 577-591.
51. Kenny EF, Quinn SR, Doyle SL, Vink PM, van Eenennaam H, et al. (2013) Bruton's tyrosine kinase mediates the synergistic signalling between TLR9 and the B cell receptor by regulating calcium and calmodulin. PLoS One 8: e74103.
52. Cancro MP (2009) Signalling crosstalk in B cells: managing worth and need. Nat Rev Immunol 9: 657-661.
53. Schweighoffer E, Vanes L, Nys J, Cantrell D, McCleary S, et al. (2013) The BAFF receptor transduces survival signals by co-opting the B cell receptor signaling pathway. Immunity 38: 475-488.
54. Davidson A (2010) Targeting BAFF in autoimmunity. Curr Opin Immunol 22: 732-739.
55. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745. (Pubitemid 32015992)
56. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, et al. (2012) Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485: 251-255.
57. Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, et al. (1995) Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270: 2008-2011. (Pubitemid 26097194)
58. Sakurai H (2012) Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 33: 522-530.
59. Wu J, Powell F, Larsen NA, Lai Z, Byth KF, et al. (2013) Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol. ACS Chem Biol 8: 643-650.
60. Shinners NP, Carlesso G, Castro I, Hoek KL, Corn RA, et al. (2007) Bruton's tyrosine kinase mediates NF-kappa B activation and B cell survival by B cellactivating factor receptor of the TNF-R family. J Immunol 179: 3872-3880.
61. O'Garra A, Stapleton G, Dhar V, Pearce M, Schumacher J, et al. (1990) Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10. Int Immunol 2: 821-832. (Pubitemid 20307067)
62. Pistoia V (1997) Production of cytokines by human B cells in health and disease. Immunol Today 18: 343-350.
63. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, et al. (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1: 475-482.
64. Lund FE, Randall TD (2010) Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol 10: 236-247.
65. Kalampokis I, Yoshizaki A, Tedder TF (2013) IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther 15 Suppl 1: S1.
66. Mauri C, Bosma A (2012) Immune regulatory function of B cells. Annu Rev Immunol 30: 221-241.
67. Jackson SM, Harp N, Patel D, Wulf J, Spaeth ED, et al. (2009) Key developmental transitions in human germinal center B cells are revealed by differential CD45RB expression. Blood 113: 3999-4007.
68. Lin L, Gerth AJ, Peng SL (2004) CpG DNA redirects class-switching towards "Th1-like" Ig isotype production via TLR9 and MyD88. Eur J Immunol 34: 1483-1487. (Pubitemid 39256028)
69. He B, Qiao X, Cerutti A (2004) CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J Immunol 173: 4479-4491. (Pubitemid 39280678)
70. Jegerlehner A, Maurer P, Bessa J, Hinton HJ, Kopf M, et al. (2007) TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 178: 2415-2420. (Pubitemid 46233441)
71. Zikherman J, Parameswaran R, Weiss A (2012) Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature 489: 160-164.
72. Galligan CL, Siebert JC, Siminovitch KA, Keystone EC, Bykerk V, et al. (2009) Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy. PLoS One 4: e6703.
73. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, et al. (2009) Activation profile of intracellular mitogen-activated protein kinases in peripheral lymphocytes of patients with systemic lupus erythematosus. J Clin Immunol 29: 738-746.